Exicure, Inc. Added to Russell 2000® Index
June 29 2020 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced that it has been added to the Russell
2000® index. This addition was effective June 26, 2020.
“We are pleased that Exicure has reached this important
milestone,” said Dr. David Giljohann, Exicure’s Chief Executive
Officer. “We look forward to telling a growing set of investors
about our clinical progress in neurology, oncology, and
ophthalmology using our genetic medicines,” concluded Dr.
Giljohann.
The Russell U.S. Indexes are widely used by investment managers
and institutional investors for passive funds and investment
products and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell
U.S. Indexes. For more information on the Russell Indexes, please
visit the “Russell Reconstitution” section on the FTSE Russell
website at www.ftserussell.com.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is based outside of Chicago, IL and also has an office in
Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200629005156/en/
Media: MacDougall Karen Sharma 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024